Clinical Trial Update: DWP708 for Treating Epidermal Growth Factor Receptor Inhibitor Related Skin Toxicities [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for DWP708 targeting skin toxicities related to epidermal growth factor receptor inhibitors, with completed status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rash Acneiform

Drugs mentioned

• DWP708

Snippet

Sponsor: Daewoong Pharmaceutical Co. LTD. | Conditions: Rash Acneiform | Phase 2 | Status: COMPLETED